ArticleFood science & nutrition2025
Tongjiang Hewei Decoction Improves Airway Hyperresponsiveness in Gastroesophageal Reflux Cough by Inhibiting ADAM33 and Epac1/Rap1 Pathway.
Article in Food science & nutrition, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Tongjiang Hewei Decoction Improves Airway Hyperresponsiveness in Gastroesophageal Reflux Cough by Inhibiting ADAM33 and Epac1/Rap1 Pathway.Food science & nutrition · 2025Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Gastroesophageal reflux disease is a common condition that can lead to various complications, with gastroesophageal reflux cough (GERC) being one of the notable manifestations. Despite conventional therapies targeting acid suppression, recurrence and incomplete efficacy remain significant challenges. Tongjiang Hewei Decoction (THD), a traditional Chinese formulation, has shown clinical promise in alleviating GERD-related symptoms. However, its therapeutic mechanisms in GERC remain unexplored. In this study, the airway hyperresponsiveness (AHR) guinea pig model was constructed by infusing hydrochloric acid into the lower esophagus. Transcriptome sequencing was used to identify THD-related possible pathways in GERC. Lung resistance was measured to evaluate lung function. Hematoxylin-eosin staining, immunohistochemistry, real-time fluorescence quantitative polymerase chain reaction, and western blotting were employed to assess airway remodeling. Airway smooth muscle cells were isolated to further investigate the effects of THD in vitro. In vivo assay indicated that THD reduced lung resistance and attenuated bronchial wall thickening, mucus hypersecretion, and inflammatory infiltration in a dose-dependent manner. Mechanistically, THD suppressed ADAM33, RhoA/ROCK, and Epac1/Rap1 pathways in vivo, correlating with reduced α-SMA and sm-MHC expression. Transcriptomic analysis revealed that THD exerted its effects through the Epac1/Rap1 signaling pathway. The Rap1 activator reversed THD's anti-AHR effects. In vitro, THD inhibited contractile protein synthesis via ADAM33 silencing, while ADAM33 overexpression abolished this effect. Collectively, THD alleviated GERC-induced AHR through dual modulation of the ADAM33/RhoA/ROCK axis and Epac1/Rap1 signaling, providing novel mechanistic insights into its therapeutic potential. These findings position THD as a multifaceted candidate for GERC management, bridging traditional medicine with modern molecular pharmacology.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.